Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

PHAT Stock Forecast


Phathom Pharmaceuticals stock forecast is as follows: an average price target of $25.83 (represents a 36.38% upside from PHAT’s last price of $18.94) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

PHAT Price Target


The average price target for Phathom Pharmaceuticals (PHAT) is $25.83 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $12.00. This represents a potential 36.38% upside from PHAT's last price of $18.94.

PHAT Analyst Ratings


Buy

According to 11 Wall Street analysts, Phathom Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PHAT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

Phathom Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 08, 2024Paul ChoiGoldman Sachs$12.00$11.752.13%-36.64%
Jul 19, 2024Matthew CaufieldH.C. Wainwright$28.00$10.95155.82%47.84%
May 02, 2024Annabel SamimyStifel Nicolaus$24.00$9.76145.90%26.72%
Jan 05, 2024Joseph StringerNeedham$26.00$8.99189.21%37.28%
Jan 04, 2023-BMO Capital$35.00$11.99191.91%84.79%
Jan 04, 2023-Needham$25.00$11.99108.51%32.00%
Nov 14, 2022-BMO Capital$38.00$10.65256.81%100.63%
Nov 11, 2022-Guggenheim$30.00$10.78178.29%58.39%
Row per page
Go to

The latest Phathom Pharmaceuticals stock forecast, released on Aug 08, 2024 by Paul Choi from Goldman Sachs, set a price target of $12.00, which represents a 2.13% increase from the stock price at the time of the forecast ($11.75), and a -36.64% decrease from PHAT last price ($18.94).

Phathom Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts-14
Avg Price Target-$12.00$22.50
Last Closing Price$18.94$18.94$18.94
Upside/Downside-100.00%-36.64%18.80%

In the current month, the average price target of Phathom Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Phathom Pharmaceuticals's last price of $18.94. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 08, 2024Goldman SachsNeutralNeutralHold
Jul 19, 2024H.C. WainwrightBuyBuyHold
Jan 05, 2024NeedhamBuyBuyHold
May 11, 2023William Blair-Market PerformDowngrade
May 11, 2023RBC Capital-OutperformUpgrade
May 11, 2023BTIG-SellDowngrade
May 11, 2023Piper Sandler-NeutralDowngrade
May 11, 2023JMP Securities-PerformDowngrade
May 11, 2023Goldman Sachs-SellDowngrade
May 11, 2023Evercore ISI-OutperformUpgrade
Row per page
Go to

Phathom Pharmaceuticals's last stock rating was published by Goldman Sachs on Aug 08, 2024. The company gave PHAT a "Neutral" rating, the same as its previous rate.

Phathom Pharmaceuticals Financial Forecast


Phathom Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22
Revenue--------$682.00K-
Avg Forecast$54.50M$44.75M$39.27M$26.43M$22.37M$12.61M$5.68M$1.63M$400.89K$211.00K
High Forecast$54.50M$44.75M$39.27M$26.43M$22.37M$13.49M$5.68M$1.63M$400.89K$211.00K
Low Forecast$54.50M$44.75M$39.27M$26.43M$22.37M$11.43M$5.68M$1.63M$400.89K$211.00K
# Analysts3333454131
Surprise %--------1.70%-

Phathom Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.63M, with a low forecast of $1.63M, and a high forecast of $1.63M. PHAT's average Quarter revenue forecast represents a 138.95% increase compared to the company's last Quarter revenue of $682.00K (Dec 23).

Phathom Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22
# Analysts3333454131
EBITDA--------$52.72M$-37.78M
Avg Forecast$32.70M$26.85M$23.56M$15.86M$13.42M$7.57M$3.41M$977.79K$240.54K$-33.88M
High Forecast$32.70M$26.85M$23.56M$15.86M$13.42M$8.10M$3.41M$977.89K$240.54K$-27.11M
Low Forecast$32.70M$26.85M$23.56M$15.86M$13.42M$6.86M$3.41M$977.68K$240.54K$-40.66M
Surprise %--------219.18%1.11%

1 analysts predict PHAT's average Quarter EBITDA for Mar 24 to be $977.79K, with a high of $977.89K and a low of $977.68K. This is -98.15% lower than Phathom Pharmaceuticals's previous annual EBITDA (Dec 23) of $52.72M.

Phathom Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22
# Analysts3333454131
Net Income--------$121.88M$-43.42M
Avg Forecast$-41.28M$-49.48M$-62.46M$-71.83M$-76.42M$-86.00M$-77.29M$-77.33M$-63.08M$-36.47M
High Forecast$-41.28M$-49.48M$-62.46M$-71.83M$-76.42M$-82.71M$-77.29M$-77.33M$-58.28M$-29.18M
Low Forecast$-41.28M$-49.48M$-62.46M$-71.83M$-76.42M$-88.74M$-77.29M$-77.33M$-67.87M$-43.77M
Surprise %---------1.93%1.19%

Phathom Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-77.33M, with a range of $-77.33M to $-77.33M. PHAT's average Quarter net income forecast represents a -163.45% decrease compared to the company's last Quarter net income of $121.88M (Dec 23).

Phathom Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22
# Analysts3333454131
SG&A--------$57.00M$20.25M
Avg Forecast$1.93B$1.58B$1.39B$935.09M$791.35M$446.14M$200.97M$57.66M$14.18M$7.47M
High Forecast$1.93B$1.58B$1.39B$935.09M$791.35M$477.44M$200.97M$57.67M$14.18M$7.47M
Low Forecast$1.93B$1.58B$1.39B$935.09M$791.35M$404.51M$200.96M$57.66M$14.18M$7.47M
Surprise %--------4.02%2.71%

Phathom Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $57.66M, based on 1 Wall Street analysts, with a range of $57.66M to $57.67M. The forecast indicates a 1.17% rise compared to PHAT last annual SG&A of $57.00M (Dec 23).

Phathom Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22
# Analysts3333454131
EPS---------$-1.14
Avg Forecast$-0.70$-0.84$-1.07$-1.23$-1.31$-1.47$-1.32$-1.32$-1.08$-0.97
High Forecast$-0.70$-0.84$-1.07$-1.23$-1.31$-1.41$-1.32$-1.32$-1.00$-0.97
Low Forecast$-0.70$-0.84$-1.07$-1.23$-1.31$-1.52$-1.32$-1.32$-1.16$-0.97
Surprise %---------0.00%1.18%

According to 1 Wall Street analysts, Phathom Pharmaceuticals's projected average Quarter EPS for Mar 24 is $-1.32, with a low estimate of $-1.32 and a high estimate of $-1.32. This represents a -55124.17% decrease compared to PHAT previous annual EPS of - (Dec 23).

Phathom Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.63$70.0011011.11%Buy
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
CNSPCNS Pharmaceuticals$0.11$0.50354.55%-
IMMXImmix Biopharma$1.58$7.00343.04%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ABOSAcumen Pharmaceuticals$2.95$7.00137.29%Buy
GPCRStructure Therapeutics$39.74$92.40132.51%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
LYRALyra Therapeutics$0.26$0.5092.31%Hold
KNSAKiniksa Pharmaceuticals$21.48$36.3369.13%Buy
PHATPhathom Pharmaceuticals$18.94$25.8336.38%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
VECTVectivBio$16.87$18.006.70%Buy
AMLXAmylyx Pharmaceuticals$5.70$5.33-6.49%Buy
KRTXKaruna Therapeutics$329.83$257.50-21.93%Buy

PHAT Forecast FAQ


Yes, according to 11 Wall Street analysts, Phathom Pharmaceuticals (PHAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of PHAT's total ratings.

Phathom Pharmaceuticals (PHAT) average price target is $25.83 with a range of $12 to $35, implying a 36.38% from its last price of $18.94. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for PHAT stock, the company can go up by 36.38% (from the last price of $18.94 to the average price target of $25.83), up by 84.79% based on the highest stock price target, and down by -36.64% based on the lowest stock price target.

PHAT's highest twelve months analyst stock price target of $35 supports the claim that Phathom Pharmaceuticals can reach $30 in the near future.

Phathom Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $42.28M (high $43.17M, low $41.11M), average EBITDA is $25.37M (high $25.9M, low $24.66M), average net income is $-317M (high $-314M, low $-320M), average SG&A $1.5B (high $1.53B, low $1.45B), and average EPS is $-5.414 (high $-5.358, low $-5.461). PHAT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $164.95M (high $164.95M, low $164.95M), average EBITDA is $98.97M (high $98.97M, low $98.97M), average net income is $-225M (high $-225M, low $-225M), average SG&A $5.84B (high $5.84B, low $5.84B), and average EPS is $-3.843 (high $-3.843, low $-3.843).

Based on Phathom Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $682K, beating the average analysts forecast of $400.89K by 70.12%. Apple's EBITDA was $-167M, missing the average prediction of $240.54K by -69657.99%. The company's net income was $0, missing the average estimation of $-63.075M by -100.00%. Apple's SG&A was $117.93M, beating the average forecast of $14.18M by 731.37%. Lastly, the company's EPS was $0, missing the average prediction of $-1.077 by -100.00%. In terms of the last quarterly report (Dec 2023), Phathom Pharmaceuticals's revenue was $682K, beating the average analysts' forecast of $400.89K by 70.12%. The company's EBITDA was $52.72M, beating the average prediction of $240.54K by 21818.13%. Phathom Pharmaceuticals's net income was $121.88M, missing the average estimation of $-63.075M by -293.22%. The company's SG&A was $57M, beating the average forecast of $14.18M by 301.82%. Lastly, the company's EPS was $0.0024, missing the average prediction of $-1.077 by -100.22%